Among the non-AD patients, APOE ε4 carriers showed lower CSF Aβ42 (p = 0.018), higher T-tau/Aβ42 (p < 0.001), and higher P-tau181/Aβ42 (p = 0.002) relative to APOE ε4 non-carriers (Figures 1d1–d5; Supplementary Table). The gene discussed is MAPT; the disease is Alzheimer disease.